The CLARITY Act, the United States' primary cryptocurrency market structure legislation, faces a critical deadline of 7 August 2026 to pass the Senate before lawmakers depart for summer recess on 8 August 2026.
Apple (NASDAQ:AAPL) closed within roughly 4% of overtaking Nvidia (NASDAQ:NVDA) as the most valuable company in the United States, driven by fresh product pipeline optimization.
US President Donald Trump declared the US-Iran Memorandum of Understanding "over" on 8 July 2026, effectively terminating a diplomatic framework that had been in place for less than three weeks following its signing on 17 June 2026 during a NATO summit in Ankara, Turkey.
Nvidia (NASDAQ:NVDA) saw its equity valuation pull back to levels relative to its forward earnings capacity not seen since early 2019, before the generative artificial intelligence buildout reset broader capital market indices.
Chevron Technical Center, a division of Chevron U.S.A. (NYSE:CVX) and a subsidiary of Chevron Corporation, has finalized a technology licensing agreement allowing ZL Chemicals to commercialize its proprietary advanced chemical surfactant technology.
Baker Hughes (NASDAQ:BKR) and Kodiak Gas Services (NYSE:KGS) have finalized a multi-year strategic agreement to design and deploy custom gas turbine power solutions aimed at addressing rapid power constraints in U.S. data center and energy infrastructure markets.
Seres Therapeutics (NASDAQ:MCRB) reported positive early clinical data from a 15-patient investigator-sponsored study evaluating its microbiome candidate SER-155 in patients with immune checkpoint inhibitor-related enterocolitis.
Wrap Technologies, Inc. (NASDAQ:WRAP) announced a strategic transaction securing exclusive United States and NATO commercialization rights to Frenel Imaging’s physics-based artificial intelligence sensing technology.
Palladyne AI (NASDAQ:PDYN) reported preliminary financial results for the second quarter of fiscal 2026, with revenue increasing to approximately $5.8 million from $1 million in the same quarter of 2025.
OKYO Pharma (NASDAQ:OKYO) received positive regulatory feedback from the United States Food and Drug Administration following a Type D consultation to advance its ophthalmic candidate urcosimod into a global Phase 3 pivotal trial.
GARANTA JÁ SEU GRAFA EDGE
Sign up free to unlock this feature
Vamos ativar um teste de 30 dias do Edge como presente de boas-vindas
